Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 352

Results For "India"

4064 News Found

Granules Inc., receives ANDA approval for prazosin hydrochloride
Drug Approval | December 28, 2021

Granules Inc., receives ANDA approval for prazosin hydrochloride

The current annual U.S. market for prazosin hydrochloride 1mg, 2mg, 5mg strengths is approximately US $ 54 million, according to IQVIA/IMS Health


Cipla receives EUA for Cipmolnu
Drug Approval | December 28, 2021

Cipla receives EUA for Cipmolnu

The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use


Strides to market molnupiravir under the brand name Stripiravir
Drug Approval | December 28, 2021

Strides to market molnupiravir under the brand name Stripiravir

Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2


Dr Reddy’s receives Emergency Use Authorisation for molnupiravir
Drug Approval | December 28, 2021

Dr Reddy’s receives Emergency Use Authorisation for molnupiravir

The company will market it under the brand name Molflu


Aurobindo to manufacture and market molnupiravir
Drug Approval | December 28, 2021

Aurobindo to manufacture and market molnupiravir

The drug will be marketed under the brand name Molnaflu


Optimus Pharma to manufacture and market molnupiravir
Drug Approval | December 28, 2021

Optimus Pharma to manufacture and market molnupiravir

The company has developed the API in house at its R&D center in Hyderabad


Lupin receives U.S. FDA approval for Sevelamer Carbonate
Drug Approval | December 27, 2021

Lupin receives U.S. FDA approval for Sevelamer Carbonate

This product will be manufactured at Lupin's Goa facility in India


Covaxin receives approval for Emergency Use in Children 12-18 years
Drug Approval | December 27, 2021

Covaxin receives approval for Emergency Use in Children 12-18 years

Covaxin is formulated uniquely such that the same dosage can be administered to adults and children


Healthcare start-up Zorgers raises angel round
Startup | December 27, 2021

Healthcare start-up Zorgers raises angel round

The Home Healthcare market is expected to be US $ 14.2 by 2025


Biocon partner Equillium initiates clinical study for Itolizumab in Lupus Nephritis
Biotech | December 24, 2021

Biocon partner Equillium initiates clinical study for Itolizumab in Lupus Nephritis

Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000